Clinical trials in Jena – page 18

349 clinical trials in Jena, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Jena at a glance

349

clinical trials

Research sites1

Quick filters

349 trials in Jena

Open in trial search

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Not recruiting

Investigational

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Zigakibart
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Danazol
Sponsor:Novartis Pharma AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Eltrombopag
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Lavender Oil
Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:SAR442970
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pelacarsen
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Jena

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on multiple myeloma, prostate cancer, and gastric cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for various cancer types.

Hematologic Malignancies
Solid Tumors
Targeted Therapies

Innovative treatments including antibody-drug conjugates and immunotherapy combinations for improved patient outcomes.

02 Cardiovascular Studies

Research investigating treatments for hypertrophic cardiomyopathy and advanced cardiovascular disease. Trials exploring new approaches to reduce major cardiovascular events and improve patient quality of life.

Heart Disease Management
Cardiovascular Risk Reduction
Novel Therapeutic Approaches

Focus on both preventive measures and treatment of established cardiovascular conditions.

03 Autoimmune Disorders

Clinical investigations of treatments for systemic lupus erythematosus, Sjögren's Disease, and other autoimmune conditions. Studies evaluating new biological therapies and targeted treatments.

Inflammatory Diseases
Immunotherapy
Disease-Modifying Treatments

Comprehensive research into improving treatment outcomes for patients with chronic autoimmune conditions.

Back to Germany All countries